Wednesday, July 8, 2026

biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR

Vir Biotechnology

Vir Biotechnology clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1800 Owens St, Suite 900, San Francisco, California 94158, US HQ
2016 Founded
479 Employees
Public company Type
VIR · NYSE Ticker
Company details
Status
Public
HQ
1800 Owens St, Suite 900, San Francisco, California 94158, US
Founded
2016
Employees
479
Programs
34
Drugs
17
Patents
6
Intelligence · Clinical Programs

Vir Biotechnology projects

17 ClinicalTrials.gov programs sponsored by Vir Biotechnology.

Vir Biotechnology has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial
  2. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial
  3. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial
  4. PEG-IFNα

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial
  5. Sotrovimab

    Vir Biotechnology

    COVID-19

    phase 2 mab terminated

    1 trial
  6. Sotrovimab (Gen1)

    Vir Biotechnology

    Covid19

    phase 2 mab completed

    1 trial
  7. Tenofovir Alafenamide

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial
  8. VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial
  9. VIR-2218

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial
  10. VIR-2218

    Vir Biotechnology

    Hepatitis D, Chronic

    phase 2 small molecule active

    1 trial
  11. VIR-2218-1006

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial
  12. VIR-2482 (450 mg)

    Vir Biotechnology

    Influenza A

    phase 2 mab terminated

    1 trial
  13. VIR-3434

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial
  14. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial
  15. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial
  16. VIR-CHDV-V206

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial
  17. VIR-MHB1-V200

    Vir Biotechnology

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Vir Biotechnology have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.